Increasing evidence has proven that ADAR2 can block CSC proliferation by inactivating podocalyxin-like (PODXL) in gastric cancer and inhibiting COPA (coatomer protein complex, subunit α) in HCC [150, 151]. This evidence concerns the gene PODXL and hepatocellular carcinoma.